#ShionogiCoLtd

In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase), realizing growth in both revenue and profit.

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.

Shionogi has acquired the Edaravone business for the treatment of amyotrophic lateral sclerosis and other conditions from Tanabe Pharma, obtaining full global rights. The business is expected to contribute to revenue and profits from fiscal year 2026 onward.

As of September 1, 2025, Shionogi & Co., Ltd. completed the acquisition of all shares of Torii Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.